Pfizer extens another offer for King; IntelliPharmaCeutics raises $12M;

 @FierceBiotech: MannKind slammed with FDA demand for new Afrezza trials. Item | Follow @FierceBiotech

 @JohnCFierce: Rodman's Simeonidis sees an 18 month delay on Afrezza, calls on the FDA to make the CRLs public. Amen on that. Follow @JohnCFierce

> IntelliPharmaCeutics has secured $12 million in financing via common stock sales to H&Q Healthcare Investors and H&Q Life Science Investors. Stock units were valued at $2.50 each for 4.8 million shares. IntelliPharmaCeutics release

> Pfizer subsidiary Parker Tennessee has extended its tender offer for all outstanding stock shares of King Pharmaceuticals to 5 p.m. on Jan. 28. If the offer is accepted, the companies plan to merge. Pfizer release

> There is no cure for the deadly ebola virus, but University of Illinois at Chicago scientists may have figured out a way to prevent it from entering human cells. Report

> Add another nano-prefixed word to the lexicon: NanoSponges. This one comes courtesy of an international team of researchers from the U.S. and Italy. They've come up with "sponges" that can sop up a potential cancer biomarker before enzymes in the blood can break it down, making it undetectable. Story

> CSF Therapeutics, a traumatic brain injury and stroke treatment company spun out from Cleveland Clinic, has shut down. News

And Finally... Breakfast may be the most important meal of the day, but don't overdo it. According to a new German study, big breakfasts didn't stop participants from overloading calories later in the day. Article